Feedback PLC Re: Media Articles
24 January 2017 - 12:28AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
23 January 2017
23 January 2017
Feedback plc
("Feedback" or the "Company")
Re: Media Articles
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to update shareholders following the recent media
articles regarding the use of multi-parametric MRI scans for the
diagnosis of prostate cancer.
It was widely reported in the national press and on the BBC
website on 20 January 2017 that a trial led by Mr Hashim Ahmed, MRC
Clinical Scientist and Honorary Consultant Urological Surgeon at
University College London ("UCL") found that over a quarter of men
with a clinical suspicion of prostate cancer could avoid a biopsy
if they undergo an MRI scan first.
Around 100,000 men are sent for a biopsy each year in Britain
following blood tests showing a raised prostate-specific antigen
(PSA) score which suggest prostate cancer might be present. But
many will not have an aggressive tumour or cancer at all and run
the risk of developing sepsis or urinary problems through the
unnecessary exploratory surgery.
Dr Balaji Ganeshan, Director of New Business at Feedback and
Senior Imaging Scientist at UCL's Institute of Nuclear Medicine,
believes that the MRI scan analysis for prostate cancer could be
improved further, according to data from another recently published
study from UCL which included the use of TexRAD texture analysis
software.
Typically up to 1,000 multi-parametric (mp) MRI images are taken
per patient, looking at tumour size, how densely packed its cells
are and its blood supply. There is an essential need to identify
tumours in the transition zone of the prostate and differentiate
between those of low clinical significance not requiring immediate
treatment and those of high clinical significance which are
generally aggressive tumours requiring treatment. This task of
identification is difficult even for an experienced
radiologist.
In a separate UCL retrospective study of 67 prostate cancer
patients published in September 2016, it was shown that TexRAD
analysis of mp-MRI images may be able to identify the presence of
clinically significant prostate cancers in the transition zone and
therefore could potentially assist in optimising the prostate
radiologist's workflow.
A further UCL study was presented at the International Society
for Magnetic Resonance in Medicine (ISMRM 2016) in Singapore which
demonstrated the application of TexRAD analysis of mp-MRI in
peripheral zone prostate cancers in 66 patients.
Dr Ganeshan stated, "Approximately 30% of mp-MRI scans for
peripheral zone prostate cancer are scored as 'equivocal'. TexRAD
analysis of prostate cancers in the peripheral zone on mp-MRI scans
may differentiate which of these 'equivocal' cancers are clinically
significant requiring further treatment and which are insignificant
not requiring treatment. We believe the use of TexRAD software
could be a step forward along the road to enhancing the MRI
prostate scan reporting process."
Further information on the UCL studies and other TexRAD research
papers can be found on the links below:
http://tinyurl.com/hy3bs2p
http://dev.ismrm.org/2016/2496.html
http://texrad.com/papers-presentations /
For further information contact:
Feedback plc Tel: 01954 718072
Alastair Riddell
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABJMJTMBTTBRR
(END) Dow Jones Newswires
January 23, 2017 08:28 ET (13:28 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2024 to May 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From May 2023 to May 2024